3 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 3 of 3 clinical reviews.
Complete regulatory history of Belsomra (suvorexant), the first dual orexin receptor antagonist approved by the FDA. Covers clinical trials, advisory committee votes, label changes, and post-market safety data.
A comprehensive review of suvorexant (Belsomra) regulatory approvals worldwide, including FDA scheduling, EMA assessment, Japanese approval, label requirements, and post-market safety surveillance data.
A clinical review of suvorexant (Belsomra) regulatory history, patent litigation, FDA dose controversies, label restrictions, and post-market safety surveillance data.